BCYC
What one share of Bicycle Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage pharmaceutical company developing a novel class of medicines, which we refer to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry.
Bicycle Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.88 |
|---|---|
| Profit | −$2.74 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$3.00 |
| Dividends | $0.00 |
| Cash and investments | $7.31 |
| Book value | $7.31 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $6.18 | −$48.81 | $3.34 | −$7.59 | — | −$141.64 |
| 2018 | $16.26 | −$49.78 | $2.70 | −$62.12 | — | −$85.70 |
| 2019 | $1.25 | −$2.77 | $0.14 | −$2.73 | — | $5.18 |
| 2020 | $0.54 | −$2.66 | $0.06 | −$0.99 | — | $4.53 |
| 2021 | $0.47 | −$2.67 | $0.08 | −$0.67 | $0.00 | $11.71 |
| 2022 | $0.49 | −$3.80 | $0.64 | −$3.54 | $0.00 | $9.06 |
| 2023 | $0.76 | −$5.08 | $0.08 | −$1.79 | $0.00 | $8.74 |
| 2024 | $0.61 | −$2.90 | $0.02 | −$2.85 | $0.00 | $11.48 |
| 2025 | $1.05 | −$3.16 | $0.03 | −$3.64 | $0.00 | $8.79 |